Papp KA, et al. - The aim of this trial was to assess the effect of previous biologic exposure on the effectiveness and safety of brodalumab and ustekinumab in moderate-to-severe plaque psoriasis. Regardless of prior biologic therapy, effectiveness of brodalumab 210 mg Q2W was similar. At week 12, almost twice as many patients achieved Psoriasis Area and Severity Index (PASI) 100 or complete clearance, compared with ustekinumab. It was determined that the differences were most noticeable where previous biologics had failed. Both the treatments were noted to be well tolerated.